Harbor Capital Advisors, Inc. Fate Therapeutics Inc Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $13,607 - $32,097	3,844 Added 24.75%	19,375 $142,000
Q4 2023 Jan 08, 2024	BUY	$1.65 - $3.94 $1,196 - $2,856	725 Added 4.9%	15,531 $58,000
Q3 2023 Oct 20, 2023	BUY	$2.02 - $5.04 $5,409 - $13,497	2,678 Added 22.08%	14,806 $31,000
Q2 2023 Jul 11, 2023	BUY	$4.76 - $6.59 $5,388 - $7,459	1,132 Added 10.29%	12,128 $57,000
Q1 2023 Apr 26, 2023	BUY	$4.24 - $11.12 $347 - $911	82 Added 0.75%	10,996 $62,000
Q4 2022 Jan 20, 2023	SELL	$9.86 - $23.83 $2,287 - $5,528	-232 Reduced 2.08%	10,914 $0
Q3 2022 Oct 28, 2022	SELL	$21.04 - $36.06 $6,438 - $11,034	-306 Reduced 2.67%	11,146 $250,000
Q2 2022 Jul 26, 2022	SELL	$17.78 - $42.39 $22,331 - $53,241	-1,256 Reduced 9.88%	11,452 $284,000
Q1 2022 Apr 28, 2022	SELL	$29.67 - $60.28 $55,453 - $112,663	-1,869 Reduced 12.82%	12,708 $493,000
Q4 2021 Feb 04, 2022	BUY	$47.84 - $64.34 $697,363 - $937,884	14,577 New	14,577 $853,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.